Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 28.
doi: 10.1007/s00392-025-02711-7. Online ahead of print.

Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonists in dialysis patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis

Tian Li  1 , Tong Li  2 , Yujun Xu  3 , Diona Gjermeni  1 , Lukas Heger  1 , Dirk Westermann  1 , Christoph B Olivier  4
Affiliations

Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonists in dialysis patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis

Tian Li et al. Clin Res Cardiol. .

Abstract

Aims: For patients with atrial fibrillation (AF) and preserved renal function, direct oral anticoagulants (DOACs) are superior to vitamin K antagonists (VKAs) for stroke prevention. However, the evidence in patients with end-stage kidney disease (ESKD) on dialysis remains inconclusive. In this systematic review and meta-analysis, we aim to compare the efficacy and safety of DOACs and VKAs in dialysis patients with nonvalvular AF.

Methods and results: We conducted a systematic literature review of publications comparing DOACs and VKAs in dialysis patients with nonvalvular AF. Data of RCTs and cohort studies were synthesized separately. Outcomes were reported as risk ratios with 95% confidence intervals. Heterogeneity was assessed using I2 statistics. Ten studies were included in this meta-analysis: 4 RCTs (DOACs, 269 patients; VKAs, 217) and 6 cohort studies (DOACs, 7039 patients; VKAs, 22,983). In RCTs, the risk for major bleeding was significantly lower with DOACs compared with VKAs (RR 0.64, 95% CI 0.42-0.99, I2 = 0%). In cohort studies, DOAC was associated with a lower risk for all-cause death compared with VKAs; however, with high heterogeneity (RR 0.78, 95% CI 0.62-0.98, I2 = 80%). No significant differences were found regarding ischemic stroke or systemic embolism and gastrointestinal bleeding.

Conclusion: In dialysis patients with nonvalvular AF, DOACs were associated with significantly reduced risk for major bleeding in RCTs and significantly reduced risk for all-cause death in cohort studies. These findings suggest that DOACs may provide a higher net clinical benefit compared with VKAs in dialysis patients.

Keywords: Anticoagulation; Atrial fibrillation; Chronic kidney failure; Dialysis; Direct oral anticoagulant; Vitamin K antagonist.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: Since this work is a systematic review of published literature and uses published data, no additional ethics approval was required. Competing interests: Financial interests: Christoph B. Olivier reports research support from Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, University of Freiburg, Else Kröner-Fresenius Stiftung, and Haemonetics and received honoraria from Bayer Vital GmbH, BMS, Böhringer Ingelheim, Daiichi Sankyo, Ferrer, Janssen, and Viatris. Dirk Westermann received honoraria from Abiomed, AstraZeneca, Meril, and Medtronic. All other authors report no disclosures. Non-financial interests: Dirk Westermann is an Editorial Board Member of Clinical Research in Cardiology.

Similar articles

See all similar articles

References

    1. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM (2010) Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77(12):1098–1106. https://doi.org/10.1038/ki.2009.477 - DOI
    1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285(18):2370–2375. https://doi.org/10.1001/jama.285.18.2370 - DOI
    1. Weenig RH, Sewell LD, Davis MDP, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56(4):569–579. https://doi.org/10.1016/j.jaad.2006.08.065 - DOI
    1. Van Ganse E, Danchin N, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Lefevre C, Cotté FE et al (2020) Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: the NAXOS study. Stroke 51(7):2066–2075. https://doi.org/10.1161/STROKEAHA.120.028825 - DOI
    1. Ribic C, Crowther M (2016) Thrombosis and anticoagulation in the setting of renal or liver disease. Hematology 2016(1):188–195. https://doi.org/10.1182/asheducation-2016.1.188 - DOI

LinkOut - more resources